Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
94d3Dg9KrwEJbdJQ
Listen
